Small ubiquitin‐like modifier/sentrin‐specific peptidase 1 associates with chemotherapy and is a risk factor for poor prognosis of non‐small cell lung cancer

Liu, Keyuan; Zhang, Jing; Wang, Hao

doi:10.1002/jcla.22611

Cited by 16 publications

(12 citation statements)

References 33 publications

(80 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dong et al revealed that SENP1 promotes the proliferation of renal clear cell carcinoma by activating glycolysis ( 32 ). Liu et al demonstrated that the high expression of SENP1 protein in non-small cell lung cancer (NSCLC) tissues, and SENP1 protein is a risk factor for poor prognosis of NSCLC ( 33 ). Cai et al showed that the variation of SENP1 in the Chinese population is not related to the risk of breast cancer, but has a specific impact on the clinicopathological characteristics of breast cancer.…”

Section: Discussionmentioning

confidence: 99%

Plasma Exosome-Derived Sentrin SUMO-Specific Protease 1: A Prognostic Biomarker in Patients With Osteosarcoma

Wang

Song

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThe exosomes contain many important proteins that can be used for early tumor diagnosis or patient prognosis analysis. In this study, we investigated plasma exosome-derived sentrin SUMO-specific protease 1 (SENP1) levels as a prognostic biomarker in patients with osteosarcoma.MethodsThe expression of SENP1 protein in osteosarcoma tissues and adjacent tissues was detected by immunohistochemistry (IHC). The exosomes were identified by transmission electron microscopy, nanoparticle tracking analysis, and western blotting. ELISA was used to detect plasma exosome-derived SENP1 levels to assess prognosis in patients with osteosarcoma.ResultsIHC showed that the positive expression rate of SENP1 in osteosarcoma tissues was 88.33%, whereas that in adjacent tissues was 46.67% (P < 0.05). Plasma exosome-derived SENP1 levels were related to tumor size, tumor location, necrosis rate, pulmonary metastasis, and surgical stage. Both disease-free survival (DFS) and overall survival (OS) were worse in patients who had higher plasma exosome-derived SENP1 levels compared with those in patients with lower plasma exosome-derived SENP1 levels (P < 0.001). The area under the receiver operating characteristic curve (AUROC) of plasma exosome-derived SENP1, as 1-year DFS and 3-year DFS prognostic biomarkers, was 0.90 (95% CI: 0.83–0.98) and 0.96 (95% CI: 0.94–0.99), respectively. As to OS, the AUROC of plasma exosome-derived SENP1 for 1-year and 3-year prediction was 0.90 (95% CI: 0.82–0.99) and 0.96 (0.93–0.98), respectively. The plasma exosome-derived SENP1 was better than plasma SENP1 as a prognostic biomarker both in DFS and OS.ConclusionsOur findings show that the plasma exosome-derived SENP1 may serve as a novel and independent prognostic predictor in clinical applications.

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma Exosome-Derived Sentrin SUMO-Specific Protease 1: A Prognostic Biomarker in Patients With Osteosarcoma

Wang

Song

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…The overexpression of SENP1 contributed to chemoradiotherapy resistance in non-small cell lung cancer. 30 In addition, SENP1 could also promote renal cell carcinoma tumorigenesis. 31 In this study, we revealed that SENP1 was overexpressed in CRC tissues and upregulated by MCM3AP-AS1.…”

Section: Discussionmentioning

confidence: 99%

“…SENP1 is a deSUMOylation enzyme that plays a critical role in DNA replication, cell cycle, and hypoxic response. The overexpression of SENP1 contributed to chemoradiotherapy resistance in non‐small cell lung cancer 30 . In addition, SENP1 could also promote renal cell carcinoma tumorigenesis 31 .…”

Section: Discussionmentioning

confidence: 99%

Long noncoding RNA MCM3AP‐AS1 enhances cell proliferation and metastasis in colorectal cancer by regulating miR‐193a‐5p/SENP1

et al. 2021

View full text Add to dashboard Cite

show abstract

“…HNK was found to inhibit the proliferation of HCC cells via G0/G1 cell cycle arrest with p21/p53 up-regulation [ 55 ]. SENP1 is now considered as a valid anticancer target, overexpressed in certain cancer (like non-small cell lung [ 127 ] and pancreatic [ 128 ] cancers) and a promotor of HCC [ 129 ]. Small molecules targeting SENP1 are actively searched [ 130 – 132 ].…”

Section: Discussionmentioning

confidence: 99%

Hinokiflavone and Related C–O–C-Type Biflavonoids as Anti-cancer Compounds: Properties and Mechanism of Action

Goossens

Bailly

2021

Nat. Prod. Bioprospect.

View full text Add to dashboard Cite

Biflavonoids are divided in two classes: C–C type compounds represented by the dimeric compound amentoflavone and C–O–C-type compounds typified by hinokiflavone (HNK) with an ether linkage between the two connected apigenin units. This later sub-group of bisflavonyl ethers includes HNK, ochnaflavone, delicaflavone and a few other dimeric compounds, found in a variety of plants, notably Selaginella species. A comprehensive review of the anticancer properties and mechanism of action of HNK is provided, to highlight the anti-proliferative and anti-metastatic activities of HNK and derivatives, and HNK-containing plant extracts. The anticancer effects rely on the capacity of HNK to interfere with the ERK1-2/p38/NFκB signaling pathway and the regulation of the expression of the matrix metalloproteinases MMP-2 and MMP-9 (with a potential direct binding to MMP-9). In addition, HNK was found to function as a potent modulator of pre-mRNA splicing, inhibiting the SUMO-specific protease SENP1. As such, HNK represents a rare SENP1 inhibitor of natural origin and a scaffold to design synthetic compounds. Oral formulations of HNK have been elaborated to enhance its solubility, to facilitate the compound delivery and to enhance its anticancer efficacy. The review shed light on the anticancer potential of C–O–C-type biflavonoids and specifically on the pharmacological profile of HNK. This compound deserves further attention as a regulator of pre-mRNA splicing, useful to treat cancers (in particular hepatocellular carcinoma) and other human pathologies.

show abstract

Small ubiquitin‐like modifier/sentrin‐specific peptidase 1 associates with chemotherapy and is a risk factor for poor prognosis of non‐small cell lung cancer

Cited by 16 publications

References 33 publications

Plasma Exosome-Derived Sentrin SUMO-Specific Protease 1: A Prognostic Biomarker in Patients With Osteosarcoma

Plasma Exosome-Derived Sentrin SUMO-Specific Protease 1: A Prognostic Biomarker in Patients With Osteosarcoma

Long noncoding RNA MCM3AP‐AS1 enhances cell proliferation and metastasis in colorectal cancer by regulating miR‐193a‐5p/SENP1

Hinokiflavone and Related C–O–C-Type Biflavonoids as Anti-cancer Compounds: Properties and Mechanism of Action

Contact Info

Product

Resources

About